Orlando Health
- Type
- Teaching hospital
- Where
- Orlando, FL
- Medicare CCN
- 100006
- Received
- $6,866,279 in 1,270 records, 2025 ($1,451,208 general, $5,415,070 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Orlando Health, Inc. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Business registration: ORLANDO HEALTH, LLC Fuzzy (name and state)
- Nonprofit contractor: Orlando Health Inc Fuzzy (name and state)
- Plan sponsor: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Federal award recipient: ORLANDO HEALTH, INC Fuzzy (name and state)
- Federal award recipient: ORLANDO HEALTH, INC. Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying client: ORLANDO HEALTH Fuzzy (name and state)
- Lobbying registrant: ORLANDO HEALTH Fuzzy (name and state)
- Nonprofit: ORLANDO HEALTH INC Fuzzy (name and state)
- Patent assignee: Orlando Health, Inc. Fuzzy (name and state)
- Trademark owner: Orlando Health, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 150 | $1,451,208 |
| 2025 | Research payment | 1,120 | $5,415,070 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,120 | $5,415,070 |
| Grant | 34 | $748,606 |
| Space rental or facility fees (teaching hospital only) | 47 | $494,591 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 15 | $96,162 |
| Long term medical supply or device loan | 5 | $63,400 |
| Education | 4 | $25,717 |
| Debt forgiveness | 4 | $20,952 |
| Food and Beverage | 40 | $1,749 |
| Gift | 1 | $28 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $152,730 | Research payment | In-kind items and services | Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatm | 2025 |
| 2025-12-31 | AngioDynamics, Inc. | $30,000 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, CV | 2025 | |
| 2025-12-31 | Medtronic, Inc. | $18,906 | Long term medical supply or device loan | In-kind items and services | 2025 | ||
| 2025-12-31 | Stryker Corporation | $9,144 | Long term medical supply or device loan | In-kind items and services | SPY-PHI System Device, ENDOSCOPY | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $8,820 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $7,126 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $5,623 | Research payment | In-kind items and services | ENFLONSIA Drug, INFECTIOUS DISEASE | A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, an | 2025 |
| 2025-12-31 | AngioDynamics, Inc. | $3,250 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2025 | |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $1,537 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-31 | EvoEndo, Inc | $651 | Research payment | In-kind items and services | Medical Monitor (LG 1080p) Medical Supply | Use of Unsedated Nasal Endoscopy Using EvoEndo Unsedated Endoscopy System in Pediatric Patients with Suspected Celiac Di | 2025 |
| 2025-12-30 | Abbott Laboratories | $130 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-26 | Zimmer Biomet Holdings, Inc. | $2 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-25 | Janssen Research & Development, LLC | $7,920 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatmen | 2025 | |
| 2025-12-25 | Janssen Research & Development, LLC | $2,280 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatmen | 2025 | |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $4,192 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $3,013 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $3,013 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-12-24 | Orthofix Medical, Inc. | $2,000 | Research payment | Cash or cash equivalent | M6-C 2L | 2025 | |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $561 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $524 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $353 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-12-23 | PFIZER INC. | $150 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 2 STUDY OF CONTINUOUS TALAZOPARIB PLUS INTERMITTENT LOWDOSE TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY | 2025 |
| 2025-12-23 | CMS Imaging, Inc. | $2 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-22 | Janssen Research & Development, LLC | $4,555 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-12-22 | Stryker Corporation | $4,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-22 | Janssen Research & Development, LLC | $1,550 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatmen | 2025 | |
| 2025-12-22 | Janssen Research & Development, LLC | $860 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatmen | 2025 | |
| 2025-12-22 | GENZYME CORPORATION | $47 | Research payment | Cash or cash equivalent | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 | |
| 2025-12-19 | BeOne Medicines Ltd. | $22,296 | Research payment | In-kind items and services | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Ve | 2025 | |
| 2025-12-19 | BeOne Medicines Ltd. | $11,148 | Research payment | In-kind items and services | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Ve | 2025 | |
| 2025-12-19 | BeOne Medicines Ltd. | $11,148 | Research payment | In-kind items and services | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Ve | 2025 | |
| 2025-12-19 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | REMICADE Biological, Immunology | A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEV | 2025 |
| 2025-12-18 | Genentech, Inc. | $3,500 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2025 | |
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $13,394 | Research payment | Cash or cash equivalent | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab | 2025 | |
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $10,674 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 | |
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $3,000 | Research payment | Cash or cash equivalent | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients wit | 2025 | |
| 2025-12-16 | Genmab U.S., Inc. | $9,739 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) i | 2025 | |
| 2025-12-16 | Boston Scientific Corporation | $7,409 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2025 |
| 2025-12-16 | Ardelyx, Inc. | $5,000 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-12-16 | Ardelyx, Inc. | $800 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-12-16 | Medtronic, Inc. | $194 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | EMBOLISE | 2025 |
| 2025-12-12 | Janssen Biotech, Inc. | $15,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-12 | Genmab A/S | $1,000 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-12-12 | Janssen Research & Development, LLC | $810 | Research payment | Cash or cash equivalent | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed b | 2025 | |
| 2025-12-11 | PFIZER INC. | $3,500 | Research payment | Cash or cash equivalent | A LOWINTERVENTIONAL STUDY TO ASSESS PHYSICAL ACTIVITY USING DIGITAL HEALTH TECHNOLOGY IN ADULT PARTICIPANTS WITH CACHEXI | 2025 | |
| 2025-12-11 | Ferring Pharmaceuticals AS | $2,750 | Research payment | Cash or cash equivalent | REBYOTA Biological, GASTROENTEROLOGY | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational | 2025 |
| 2025-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety | 2025 | |
| 2025-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety | 2025 | |
| 2025-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,495 | Research payment | Cash or cash equivalent | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients | 2025 | |
| 2025-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $1,450 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety | 2025 | |
| 2025-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $575 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety | 2025 | |
| 2025-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $500 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety | 2025 | |
| 2025-12-10 | Merck Sharp & Dohme LLC | $4,465 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2025 |
| 2025-12-09 | FUJIFILM Healthcare Americas Corporation | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FUJIFILM Device, Medical Device | 2025 | |
| 2025-12-08 | Janssen Research & Development, LLC | $3,480 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-12-08 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,150 | Research payment | Cash or cash equivalent | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 comb | 2025 | |
| 2025-12-05 | GENZYME CORPORATION | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CEREZYME Biological, Genetic Disease | 2025 | |
| 2025-12-05 | KARL STORZ Endoscopy-America | $1,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | ABBVIE INC. | $25,000 | Grant | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-04 | Zimmer Biomet Holdings, Inc. | $8,077 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Persona Device, Knees | 2025 | |
| 2025-12-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $28,859 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with | 2025 | |
| 2025-12-03 | HELIOS CARDIO INC | $16,250 | Research payment | Cash or cash equivalent | CARDIAMEND Device, CARDIAC SURGERY | Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects (AMIOMEND) | 2025 |
| 2025-12-03 | ModernaTX, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and i | 2025 | |
| 2025-12-03 | Merge Healthcare Incorporated | $14 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2025 | |
| 2025-12-02 | Iovance Biotherapeutics, Inc. | $6,356 | Research payment | Cash or cash equivalent | Amtagvi Drug, Oncology | 117145 | 2025 |
| 2025-12-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,250 | Research payment | Cash or cash equivalent | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients | 2025 | |
| 2025-12-02 | CMS Imaging, Inc. | $14 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-01 | Iovance Biotherapeutics, Inc. | $2,322 | Research payment | Cash or cash equivalent | Amtagvi Drug, Oncology | 81990 | 2025 |
| 2025-12-01 | Iovance Biotherapeutics, Inc. | $1,000 | Research payment | Cash or cash equivalent | Amtagvi Drug, Oncology | 81990 | 2025 |
| 2025-12-01 | Genmab A/S | $1,000 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-12-01 | Genmab A/S | $575 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-28 | Boston Scientific Corporation | $15,000 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-11-28 | ModernaTX, Inc. | $11,200 | Research payment | Cash or cash equivalent | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S | 2025 | |
| 2025-11-28 | ModernaTX, Inc. | $1,179 | Research payment | Cash or cash equivalent | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S | 2025 | |
| 2025-11-28 | Janssen Research & Development, LLC | $1,006 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $4,585 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $4,323 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $4,323 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $3,406 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $3,406 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $561 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $561 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $458 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $458 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $353 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $353 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | $99 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | $4,585 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | $4,192 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | $3,013 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | $576 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | $561 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-26 | Smith+Nephew, Inc. | $500 | Research payment | Cash or cash equivalent | A Multi-Center Study in Patients Undergoing Total Hip Arthroplast with Smith & Nephew CATALYSTEM Promary Hip | 2025 | |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | $458 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | $458 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | $353 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-25 | Ascendis Pharma Endocrinology Inc | $5,000 | Research payment | Cash or cash equivalent | Skytrofa Drug, Endocrinology | SkybriGHt | 2025 |
| 2025-11-25 | Ascendis Pharma Endocrinology Inc | $1,500 | Research payment | Cash or cash equivalent | Skytrofa Drug, Endocrinology | SkybriGHt | 2025 |
| 2025-11-25 | Ascendis Pharma Endocrinology Inc | $1,000 | Research payment | Cash or cash equivalent | Skytrofa Drug, Endocrinology | SkybriGHt | 2025 |
| 2025-11-25 | Ardelyx, Inc. | $1,000 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C | 2025 |
| 2025-11-25 | Ardelyx, Inc. | $1,000 | Research payment | Cash or cash equivalent | Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old | 2025 | |
| 2025-11-25 | Ardelyx, Inc. | $500 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-11-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,869 | Research payment | Cash or cash equivalent | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 comb | 2025 | |
| 2025-11-24 | Abbott Laboratories | $1,572 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-11-24 | Ethicon Inc. | $1,000 | Research payment | Cash or cash equivalent | Safety and Performance of the OTTAVA Robotic System: A Prospective, Multi-Center Evaluation | 2025 | |
| 2025-11-21 | Genmab A/S | $8,455 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $8,279 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $7,504 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $7,348 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $7,348 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $6,407 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $4,286 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $4,286 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $4,103 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $3,946 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $3,913 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $3,756 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $3,756 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Intuitive Surgical Operations, Inc. | $3,213 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion Registry Patient Visit fees | 2025 |
| 2025-11-21 | Genmab A/S | $266 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-21 | Genmab A/S | $266 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-20 | Janssen Research & Development, LLC | $4,000 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-11-20 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-11-20 | ABBVIE INC. | $1,865 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study to Assess Adverse Events Change in Disease Activity and How Intravenous and Subcutaneous Risankizumab Moves Thro | 2025 |
| 2025-11-20 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-11-20 | EMD Serono, Inc. | $1,500 | Research payment | Cash or cash equivalent | Mavenclad Drug, Neurology | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previ | 2025 |
| 2025-11-20 | EMD Serono, Inc. | $1,200 | Research payment | Cash or cash equivalent | Mavenclad Drug, Neurology | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previ | 2025 |
| 2025-11-20 | Smith+Nephew, Inc. | $1,091 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Panta 2 Device, Extremity, Lower Plates, Screws, and Nails | 2025 | |
| 2025-11-20 | Novo Nordisk AS | $750 | Research payment | Cash or cash equivalent | Drug | 4202-HEM-301 | 2025 |
| 2025-11-20 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-20 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-20 | Genentech, Inc. | $625 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | $4,192 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | $3,013 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-19 | Novo Nordisk Inc | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | $2,947 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | $561 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | $353 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | $334 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2025 |
| 2025-11-18 | Boston Scientific Corporation | $4,445 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2025 |
| 2025-11-17 | GENZYME CORPORATION | $22,040 | Research payment | Cash or cash equivalent | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 | |
| 2025-11-17 | GENZYME CORPORATION | $14,432 | Research payment | Cash or cash equivalent | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 | |
| 2025-11-17 | Janssen Research & Development, LLC | $3,500 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2025 |
| 2025-11-17 | Genmab A/S | $680 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-17 | Genmab A/S | $300 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus D | 2025 | |
| 2025-11-14 | E.R. Squibb & Sons, L.L.C. | $11,395 | Research payment | Cash or cash equivalent | Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commer | 2025 | |
| 2025-11-14 | Intuitive Surgical Operations, Inc. | $10,300 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion Registry Patient Visit fees | 2025 |
| 2025-11-14 | Janssen Research & Development, LLC | $5,450 | Research payment | Cash or cash equivalent | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed b | 2025 | |
| 2025-11-14 | Intercept Pharmaceuticals, Inc. | $5,000 | Grant | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2025 | |
| 2025-11-14 | Curonix LLC | $2,000 | Research payment | Cash or cash equivalent | PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Device, PAIN MANAGEMENT | Double-Blinded Randomized Control Trial of Knee Pain Utilizing Sub-Threshold Peripheral Nerve Stimulation | 2025 |
| 2025-11-14 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-11-14 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-11-14 | Medical Device Business Services, Inc. | $1,091 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-13 | ABBVIE INC. | $14,934 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse | 2025 |
| 2025-11-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 comb | 2025 | |
| 2025-11-12 | ModernaTX, Inc. | $70,658 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and i | 2025 | |
| 2025-11-12 | Intuitive Surgical Operations, Inc. | $1,310 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion Registry Patient Visit fees | 2025 |
| 2025-11-12 | Intuitive Surgical Operations, Inc. | $1,310 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion Registry Patient Visit fees | 2025 |
| 2025-11-12 | Abbott Laboratories | $432 | Research payment | Cash or cash equivalent | ASSERT-IQ Device, Vascular | NCT06172699--Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study | 2025 |
| 2025-11-12 | Iovance Biotherapeutics, Inc. | $32 | Research payment | Cash or cash equivalent | Amtagvi Drug, Oncology | 81990 | 2025 |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | $4,585 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | $4,323 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | $3,406 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-10 | Janssen Research & Development, LLC | $3,000 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatmen | 2025 | |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | $561 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | $353 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-07 | Intuitive Surgical, Inc. | $11,430 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2025 | |
| 2025-11-07 | Janssen Research & Development, LLC | $3,500 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2025 |
| 2025-11-07 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-11-06 | Janssen Research & Development, LLC | $13,866 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-11-06 | Abbott Laboratories | $2,500 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | NCT03309332--AMPLATZER PFO Occluder Post Approval Study | 2025 |
| 2025-11-06 | CMS Imaging, Inc. | $53 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-06 | Genmab U.S., Inc. | $43 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) i | 2025 | |
| 2025-11-05 | Intuitive Surgical Operations, Inc. | $91,372 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Ion Registry Patient Visit fees | 2025 |
| 2025-11-05 | ModernaTX, Inc. | $33,601 | Research payment | Cash or cash equivalent | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S | 2025 | |
| 2025-11-05 | AstraZeneca Pharmaceuticals LP | $31,131 | Research payment | Cash or cash equivalent | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus t | 2025 | |
| 2025-11-05 | ModernaTX, Inc. | $6,274 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and i | 2025 | |
| 2025-11-05 | ModernaTX, Inc. | $4,585 | Research payment | Cash or cash equivalent | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S | 2025 | |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $4,585 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $4,585 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $4,323 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $4,323 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | ModernaTX, Inc. | $3,537 | Research payment | Cash or cash equivalent | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S | 2025 | |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $3,406 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $3,406 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | ModernaTX, Inc. | $917 | Research payment | Cash or cash equivalent | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S | 2025 | |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $561 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $561 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $353 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-05 | Regeneron Pharmaceuticals, Inc. | $353 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREA | 2025 |
| 2025-11-04 | E.R. Squibb & Sons, L.L.C. | $11,590 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | 2025 |
| 2025-11-03 | Janssen Research & Development, LLC | $9,110 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-11-03 | Janssen Research & Development, LLC | $2,270 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and | 2025 |
| 2025-11-03 | ModernaTX, Inc. | $1,000 | Research payment | Cash or cash equivalent | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S | 2025 | |
| 2025-10-31 | Stryker Corporation | $2,500 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PERSEVERE STUDY | 2025 |
| 2025-10-31 | Regeneron Pharmaceuticals, Inc. | $368 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplima | 2025 |
The latest 200 records of 1,270.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Orlando, FL, county Orange County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Orlando, FL | County Orange County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 319,758 | 1,471,937 | 22,416,077 |
| Population, 2020 census P1 | 307,573 | 1,429,908 | 21,538,187 |
| Median age B01002 | 35.1 | 36.6 | 42.6 |
| Under 18 B01001 | 21.4% | 21.4% | 19.5% |
| 65 and over B01001 | 11.3% | 13.0% | 21.3% |
| Households B11001 | 131,179 | 527,776 | 8,752,810 |
| Foreign born B05002 | 25.4% | 24.3% | 21.9% |
| Median household income B19013 | $72,336 | $79,719 | $74,568 |
| Median family income B19113 | $81,945 | $92,968 | $89,891 |
| Per capita income B19301 | $43,312 | $41,160 | $42,609 |
| Poverty rate B17001 | 14.7% | 13.0% | 12.6% |
| Unemployment rate B23025 | 5.2% | 5.5% | 4.8% |
| Civilian labor force B23025 | 186,466 | 803,825 | 11,016,578 |
| Mean commute (minutes) B08013 | 26.2 | 28.0 | 28.0 |
| Bachelor's degree or higher B15003 | 42.5% | 39.3% | 34.1% |
| Housing units B25001 | 148,754 | 586,805 | 10,256,470 |
| Owner-occupied B25003 | 39.5% | 56.8% | 67.6% |
| Renters B25003 | 60.5% | 43.2% | 32.4% |
| Median home value B25077 | $394,100 | $390,100 | $359,000 |
| Median gross rent B25064 | $1,747 | $1,775 | $1,669 |
| White, not Hispanic B03002 | 31.2% | 35.9% | 50.4% |
| Black B03002 | 22.2% | 19.1% | 14.6% |
| Hispanic or Latino B03002 | 35.4% | 33.8% | 27.4% |
| Asian B03002 | 4.8% | 5.3% | 2.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Orlando, FL.
Comments